Section 4 of 6
Clinical evidence
126 evidence topics · 34 sources
Study summaries
CAPTIVATE
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Primary objective stated by the investigators
Objective of the Part A interim analysis
Regulatory purpose stated by the company before the trial started
Regulatory purpose stated by the company, November 2026
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2025-02-10” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2028-12-31” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2030-12-31” (opens the source at this quote in a new tab)
“First Posted 2025-03-05” (opens the source at this quote in a new tab)
“Last Update Posted 2026-10-28” (opens the source at this quote in a new tab)
“Recruiting” (opens the source at this quote in a new tab)
“No Results Posted” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Study locations by country in the ClinicalTrials.gov record
Sites activated as of September 2026
Initiation announced by the company, March 2025
Data cut-off of the interim responder analysis
Timing guidance after the interim responder analysis, March 2026
Expected timing of Part A and Part B top-line results, November 2026
Member states, start date, and estimated end dates in the EU trial record
Status by member state in the EU trial record
“Belgium Ongoing, recruiting” (opens the source at this quote in a new tab)
“Denmark Ongoing, recruiting” (opens the source at this quote in a new tab)
“Netherlands Ongoing, recruiting” (opens the source at this quote in a new tab)
“Latvia Authorised, recruitment pending” (opens the source at this quote in a new tab)
“France Ongoing, recruiting” (opens the source at this quote in a new tab)
“Italy Ongoing, recruiting” (opens the source at this quote in a new tab)
“Germany Ongoing, recruiting” (opens the source at this quote in a new tab)
“Croatia Authorised, recruitment pending” (opens the source at this quote in a new tab)
“Bulgaria Ongoing, recruiting” (opens the source at this quote in a new tab)
“Spain Ongoing, recruiting” (opens the source at this quote in a new tab)
“Poland Ongoing, recruiting” (opens the source at this quote in a new tab)
“Romania Authorised, recruiting” (opens the source at this quote in a new tab)
Study design
Study periods and design details in the ClinicalTrials.gov record
Two-part design described by the investigators
Randomized-withdrawal design described by the company
Original design before the interim responder analysis
Design changes announced in March 2026: Part A up to 256 participants and 600 mg arm removed from Part B
Basis for the March 2026 design changes
Design changes restated in the first quarter 2026 report, May 2026
Part A resized to fewer than 200 participants, November 2026
Current design presented in November 2026
Differences from the ADHERE design stated by the company
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
“Weight range between 40 kilograms (kg) and 120 kg.” (opens the source at this quote in a new tab)
“Must be neurologically stable.” (opens the source at this quote in a new tab)
“Must have an INCAT score between 2 and 9 inclusive.” (opens the source at this quote in a new tab)
“18 Years to 75 Years” (opens the source at this quote in a new tab)
Prior treatment conditions in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Study population described by the investigators
Antinuclear antibody screening removed
Treatment
Arms and interventions in the ClinicalTrials.gov record
Part B arms before and after the March 2026 design change
Switch from prior therapy and concomitant treatment
Intravenous loading dose amount
No evidence found.
Study outcomes
Rationale for using adjusted INCAT disability score relapse as the primary endpoint
Primary outcome in the ClinicalTrials.gov record
Part A response criterion
Secondary outcomes in the ClinicalTrials.gov record
Secondary and other assessments stated by the investigators
Adjusted INCAT disability score: definition and range
“The adjusted INCAT score is applied throughout the study because changes in the function of the upper limbs from 0 (normal) to 1 (minor symptoms) or from 1 to 0 are not considered by regulatory agencies to be clinically significant in all patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The INCAT disability scale ranges from 0 (healthy) to 10 (unable to make any purposeful movements with arms or legs)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal clinically important difference of the adjusted INCAT disability score
“The results demonstrated that the MCID of the primary outcome measure, the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale, was between 0.60 and 0.72. These results, therefore, provided retrospective justification for use of the applicable cut-off of 1-point on the INCAT scale to define improvement in the ICE Trial and brings support for its continuing use in CIDP trials to this day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite these issues, MCIDs for disability measures such as INCAT, ONLS, and I-RODS have demonstrated their value through validity and clinical relevance, making them suitable for both research and clinical practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Use of the one-point adjusted INCAT threshold across CIDP trials
“13 (72.2%) used the adjusted INCAT, in all cases with a cut-off of one point in keeping with the originally derived clinically applicable result.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ONLS scale, closely related to the INCAT, was used in one study (5.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjusted INCAT endpoints in earlier CIDP maintenance trials
“The primary outcome was the percentage of patients who had maintained an improvement from baseline in adjusted INCAT disability score of 1 point or more through to week 24.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the extension phase, participants who continued to receive IGIV-C had a longer time to relapse than did patients treated with placebo (p=0.011).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Endpoint and design rationale stated by the company and investigators
Measurement properties and limitations of the INCAT disability score
“It is used frequently as a primary endpoint in inflammatory polyneuropathy clinical trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Strengths of the INCAT score include evaluation of upper and lower limb dysfunction, ease of administration (feasibility), high face validity, and high reliability. Weaknesses of the scale include concerns about methodological quality of validation studies; failure to properly capture activity limitations due to proximal arm weakness, or fatigue; heavy individual item weighting; and poor sensitivity for detection of clinically important change.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Inflammatory Rasch-built Overall Disability Scale secondary endpoint: development and responsiveness
“The R-ODS is a linearly weighted scale that specifically captures activity and social participation limitations in patients with GBS, CIDP, and MGUSP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The I-RODS more often captures clinically meaningful changes over time, with a greater magnitude of change, compared with the INCAT-ONLS disability scale in patients with GBS and CIDP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The summed raw score will subsequently be transformed to a centile score that ranges from 0 (most severe activity and social participation limitations) to 100 (no activity and social participation limitations).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inflammatory Rasch-built Overall Disability Scale threshold of 4 centile points
“Ten studies (55.6%) used the I-RODS, some with multiple MCIDs, of which 3/10 set the cut-off at 4 centile points and another 3/10 at 4 raw points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, no justification for use of an I-RODS MCID of 4 centile points could be found through previous or per-study derivation, including in the recent ADHERE trial where it was nevertheless used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Grip strength secondary endpoint: Vigorimeter validity and the 8 kPa threshold
“Good interobserver and intra-observer agreements (analysis of variance, r = 0.95-0.97) and high responsiveness (standardized response mean scores > or = 0.8) were demonstrated for the Vigorimeter.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A minimum clinically important difference cut-off value for grip strength (>8 kPa) and INCAT score (>1 point) was applied to assess the proportion of responders to IGIV-C versus placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Grip strength can be considered a sensitive tool for assessing clinically relevant changes in patients with CIDP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MCID discrepancies between ascertainment methods were, on the other hand, found for grip strength (14 kPa with the anchor-based method vs. 8 kPa using ½ SD or SE)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eleven studies (61.1%) used grip strength through Martin vigorimeter readings with an MCID cut-off exclusively of 8 kPa in 9/11” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcome measure thresholds in the 2021 EAN/PNS guideline, as reviewed
“A short list of outcome measures with cut-offs, in some cases variable, was provided as a guide. The list was mainly based on previous MCID utilization in trials and not consistently obtained from previous studies of clinically- or research-derived cut-offs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Changes used to define improvement on disability and impairment scales in the 2021 EAN/PNS guideline
“I-RODS: + ≥4 centile points” (opens the source at this quote in a new tab)
“INCAT disability scale: − ≥1 point” (opens the source at this quote in a new tab)
“MRC sum score (0-60): + ≥2 to 4 points” (opens the source at this quote in a new tab)
“Grip strength: Martin Vigorimeter: + ≥8 to 14 kPa” (opens the source at this quote in a new tab)
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated enrollment in the ClinicalTrials.gov record
Interim responder analysis size and decision criterion
Participants analyzed in the interim analysis
Sample size calculation for Part B
No evidence found.
Description of analysis sets
Interim analysis set
Last evaluable visit used for change from baseline
Analysis set for the March 2026 baseline summary
Part B analysis populations
No evidence found.
Results
Participant disposition
Early GO decision, March 2026
Outcome of the first 40 participants completing Part A
Enrollment and randomization to Part B to date
No evidence found.
Baseline characteristics
Baseline demographics and disease characteristics of the interim analysis set
| Characteristic | Claseprubart 300 mg every 2 weeks (N=40) |
|---|---|
| Age, years, mean (SD) | “56.9 (12.5)” |
| Age, years, median (range) | “59.5 (31–74)” |
| Male, n (%) | “26 (65.0)” |
| Typical CIDP, n (%) | “35 (87.5)” |
| Multifocal CIDP, n (%) | “2 (5.0)” |
| Motor CIDP, n (%) | “3 (7.5)” |
| Mean time since diagnosis, years (SD) | “4.2 (6.1)” |
| Prior treatment: SoC-treated, n (%) | “27 (67.5)” |
| Prior treatment: immunoglobulin, n (%) | “19 (47.5)” |
| Prior treatment: oral corticosteroids, n (%) | “8 (20.0)” |
| Prior treatment: SoC-refractory, n (%) | “9 (22.5)” |
| Prior treatment: treatment-naive, n (%) | “4 (10.0)” |
| INCAT, mean (SD) | “4.0 (1.21)” |
| Grip strength, kPa, mean (SD) | “41.4 (20.0)” |
| I-RODS, mean (SD) | “47.9 (13.7)” |
| MRC-SS, mean (SD) | “50.5 (5.6)” |
Race, ethnicity, and enrollment by region
No evidence found.
Efficacy results
Confirmed response rate in the first 40 participants completing Part A
Response rate against the interim target, announced June 2026
Change from Part A baseline at the last evaluable visit, by responder status
| Measure, mean (SD) | Confirmed responders (n=30) | Non-responders (n=10) |
|---|---|---|
| INCAT (decrease is improvement) | “–1.6 (0.89)” | “0.7 (1.06)” |
| Grip strength (increase is improvement) | “15.9 (12.78)” | “–7.5 (12.19)” |
| MRC-SS (increase is improvement) | “5.1 (3.93)” | “–2.3 (8.82)” |
| I-RODS (increase is improvement) | “8.9 (12.08)” | “–3.0 (10.69)” |
Secondary measures in confirmed responders
Response by prior treatment group
No evidence found.
Part B time to relapse
No evidence found.
Health-related quality of life and patient-reported outcomes
Inflammatory Rasch-built Overall Disability Scale change from Part A baseline
| Measure, mean (SD) | Confirmed responders (n=30) | Non-responders (n=10) |
|---|---|---|
| I-RODS (increase is improvement) | “8.9 (12.08)” | “–3.0 (10.69)” |
EQ-VAS and Fatigue Severity Scale results
No evidence found.
Safety results
Adverse events in the interim analysis set
Severity, serious adverse events, and discontinuations
Drug-induced lupus and serious infections, August 2026
Adverse events by type
No evidence found.
Study limitations
Summary
The only CAPTIVATE results are from an interim analysis of open-label Part A: of the first 40 participants who completed Part A with evaluable efficacy data, 30 (75%) were confirmed responders in this per-protocol interim analysis, and the company describes the summaries as preliminary. Part A has no comparator arm, so the 75% response rate and the changes in grip strength, MRC-SS, and I-RODS among responders are uncontrolled. In the randomized-withdrawal design, only Part A responders enter the placebo-controlled Part B, whose primary endpoint is time to relapse (an increase of at least 1 point in adjusted INCAT); Part B results are expected by the end of 2028 and will describe participants who first responded to claseprubart. The trial was resized after the interim analysis: in March 2026 the company announced plans, pending regulatory approval, to remove the 600 mg Part B arm and to enroll up to 256 participants in Part A (previously up to 480) to randomize 128 in Part B (previously 192); the investigators later described 1:1 randomization in Part B to claseprubart 300 mg or placebo, and in November 2026 Part A was projected to require fewer than 200 participants, while the registry still lists an estimated enrollment of 256.
Preliminary status of the interim data
Limited disclosure to preserve trial integrity
Predictive value of the interim analysis stated by the company
DNTH103-AU-001
Objective
Primary objectives in the Part A and Part B registry record
Secondary objectives in the Part A and Part B registry record
Part C objectives: pharmacokinetics after human normal immunoglobulin G
Objectives stated by the company at study start and at top-line results
Location and study date
Registration, recruitment dates, and status of Parts A and B
Study location, sponsors, and ethics committee
Registration, recruitment dates, and status of Part C
First participant dosed, November 2022
Trial initiation and top-line data dates reported by the company
Study design
Single ascending dose and multiple ascending dose parts
Randomization and blinding of Parts A and B
Part C: open-label, uncontrolled single cohort
First-in-human design described by the company
Eligibility criteria
Key inclusion criteria
Key exclusion criteria
Part C eligibility
Treatment
Planned Part A single-dose cohorts
“SAD IV1, 1 mg/kg” (opens the source at this quote in a new tab)
“SAD IV2, 3 mg/kg” (opens the source at this quote in a new tab)
“SAD IV3, 10 mg/kg” (opens the source at this quote in a new tab)
“SAD IV4, 30 mg/kg” (opens the source at this quote in a new tab)
“SAD IV5, 60 mg/kg” (opens the source at this quote in a new tab)
“SAD SC1, 300 mg” (opens the source at this quote in a new tab)
“SAD SC2, 600 mg” (opens the source at this quote in a new tab)
Planned Part B multiple-dose cohorts
Dose cohorts reported as dosed
Part C: intravenous immunoglobulin before a single dose of DNTH103
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Primary safety endpoints and adverse event grading
Safety as the purpose of a first-in-human study
Secondary pharmacokinetic, pharmacodynamic, and immunogenicity endpoints
“Maximum concentration (Cmax)” (opens the source at this quote in a new tab)
“Terminal elimination half-life (t½)” (opens the source at this quote in a new tab)
“Absolute bioavailability (Fabs)” (opens the source at this quote in a new tab)
“CH50 (complement haemolysis 50%) in serum ex vivo” (opens the source at this quote in a new tab)
“Incidence of anti-drug antibody (ADA) to DNTH103” (opens the source at this quote in a new tab)
Part C: pharmacokinetics as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment and sample size basis in the Part A and Part B registry record
Final accrual in the registry records, last updated June 2025
Participants by part reported in January 2024
Participants reported in the annual report filed March 2025
Description of analysis sets
Safety, pharmacokinetic, pharmacodynamic, and immunogenicity populations
Results
Participant disposition
Participants who completed dosing, as of December 2023
Completion of treatment after injection site reactions
Baseline characteristics
No evidence found.
Efficacy results
Pharmacokinetic results: half-life and dose proportionality
Pharmacodynamic results: classical pathway inhibition and simulated steady state
Dose selection for later trials based on phase 1 data
Part C pharmacokinetics after immunoglobulin G
No evidence found.
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Overall tolerability, serious adverse events, and infections
Adverse events reported across the eight cohorts
Injection site reactions, infusion events, and vomiting
Antinuclear antibody positivity in the 50 mg/kg intravenous cohort
Part C safety
No evidence found.
Study limitations
Summary
DNTH103-AU-001 enrolled healthy adults aged 18 to 65 years and excluded people with a history of autoimmune disease, so its safety, pharmacokinetic, and pharmacodynamic findings come from a population without the diseases claseprubart is being developed to treat, and the company states that the same results may not be seen in patients in later trials. Each dose cohort was planned with 8 participants (6 receiving DNTH103 and 2 receiving placebo); the company's top-line announcement reported 52 healthy volunteers in 7 single and multiple ascending dose cohorts, and later company documents reported 60 healthy volunteers in 8 cohorts who completed dosing as of December 2023, while the registry records a final accrual of 68 for Parts A and B and 9 for the open-label, uncontrolled Part C. The Parts A and B registry record lists recruitment in Christchurch, New Zealand, the company states that the phase 1 trial was conducted in New Zealand, and both registry records state that no documents have been uploaded by study researchers, so the available results come from company press releases, presentations, and annual reports, and no Part C result has been reported. The company states that FDA acceptance of data from trials conducted outside the United States is subject to conditions the FDA imposes.